Colobreathe

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Colistimethate natrijev

Available from:

Teva B.V.

ATC code:

J01XB01

INN (International Name):

colistimethate sodium

Therapeutic group:

Antibacterials za sistemsko uporabo,

Therapeutic area:

Cistična fibroza

Therapeutic indications:

Colobreathe je navedeno za upravljanje kronične pljučne okužbe zaradi Pseudomonas aeruginosa pri bolnikih s cistično fibrozo (CF), starih šest let in starejši. Upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Product summary:

Revision: 16

Authorization status:

Pooblaščeni

Authorization date:

2012-02-13

Patient Information leaflet

                                18
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Teva B.V.
Swensweg 5
2031 GA Haarlem
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/11/747/001 56 trdih kapsul (4 pretisni omoti s 14 kapsulami)
EU/1/11/747/002 8 trdih kapsul (1 pretisni omot z 8 kapsulami)
EU/1/11/747/003 56 trdih kapsul (7 pretisnih omotov z 8 kapsulami)
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Colobreathe
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
19
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT
1.
IME ZDRAVILA
Colobreathe 1.662.500 i.e. prašek za inhaliranje
natrijev kolistimetat
samo za inhaliranje
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Teva B.V.
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
20
B. NAVODILO ZA UPORABO
21
NAVODILO ZA UPORABO
COLOBREATHE 1.662.500 I.E. PRAŠEK ZA INHALIRANJE, TRDE KAPSULE
natrijev kolistimetat
PRED ZAČETKOM UPORABE ZDRAVILA NATANČNO PREBERITE NAVODILO, KER
VSEBUJE ZA VAS POMEMBNE
PODATKE!
-
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
-
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali
farmacevtom.
-
Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Njim bi lahko celo
škodovalo, čeprav imajo znake bolezni, podobne vašim.
-
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom
ali farmacevtom. Posvetujte se
tudi, če opazite katere koli neželene učinke, ki niso navedeni v
tem navodilu. Glejte poglavje 4.
KAJ VSEBUJE NAVODILO
1.
Kaj je zdravilo Colobreathe in za kaj ga uporabljamo
2.
Kaj morate vedeti, preden boste uporabili zdravilo Colobreathe
3.
Kako uporabljati zdravilo Colobreathe
4.
Možni nežel
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Colobreathe 1.662.500 i.e. prašek za inhaliranje, trde kapsule
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena kapsula vsebuje 1.662.500 i.e., kar ustreza približno 125 mg
natrijevega kolistimetata.
3.
FARMACEVTSKA OBLIKA
prašek za inhaliranje, trde kapsule (prašek za inhaliranje)
Trde prozorne PEG-želatinske kapsule, ki vsebujejo droben bel
prašek.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Colobreathe je indicirano za zdravljenje kroničnih pljučnih
okužb z bakterijo
_Pseudomonas _
_aeruginosa_
pri bolnikih s cistično fibrozo (CF), starih 6 let in več (glejte
poglavje 5.1).
Upoštevati je treba uradna navodila glede ustrezne uporabe
antibakterijskih učinkovin.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
_Odrasli ter otroci, stari 6 let in več _
Ena kapsula se inhalira dvakrat na dan.
Interval odmerka naj bo kar se da blizu 12 ur.
Učinkovitost zdravila Colobreathe je bila dokazana v 24 tednov
trajajoči študiji. Zdravnik lahko z
zdravljenjem nadaljuje tako dolgo, dokler meni, da ima bolnik od tega
klinične koristi.
_ _
_Okvara ledvic_
Ocenjuje se, da odmerka ni treba prilagajati (glejte poglavje 5.2).
_Okvara jeter _
Ocenjuje se, da odmerka ni treba prilagajati (glejte poglavje 5.2).
_ _
_Pediatrična populacija _
Varnost in učinkovitost zdravila Colobreathe pri otrocih, starih manj
kot 6 let, še nista bili dokazani.
Podatki niso na voljo.
Način uporabe
Samo za inhaliranje.
Zdravilo Colobreathe kapsule se uporabljajo samo z inhalatorjem za
prašek Turbospin.
Kapsule se ne smejo pogoltniti.Za zagotovitev pravilnega dajanja
zdravila mora zdravnik ali drug
zdravstveni delavec bolniku pokazati, kako uporabljati inhalator, pri
čemer se prvi odmerek uporabi
pod zdravniškim nadzorom.
V primeru sočasnih terapij naj bo vrstni red naslednji:
-
inhaliranje bronhodilatatorjev
-
fizioterapija prsnega koša
-
druga inhalacijska zdravila
3
-
zdravilo Colobreathe
4.3
KONTRAINDIKACIJE
Preobčutljivost na učinkovino, kolistinijev sul
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-10-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-10-2023
Public Assessment Report Public Assessment Report Bulgarian 07-03-2012
Patient Information leaflet Patient Information leaflet Spanish 04-10-2023
Public Assessment Report Public Assessment Report Spanish 07-03-2012
Patient Information leaflet Patient Information leaflet Czech 04-10-2023
Public Assessment Report Public Assessment Report Czech 07-03-2012
Patient Information leaflet Patient Information leaflet Danish 04-10-2023
Public Assessment Report Public Assessment Report Danish 07-03-2012
Patient Information leaflet Patient Information leaflet German 04-10-2023
Public Assessment Report Public Assessment Report German 07-03-2012
Patient Information leaflet Patient Information leaflet Estonian 04-10-2023
Public Assessment Report Public Assessment Report Estonian 07-03-2012
Patient Information leaflet Patient Information leaflet Greek 04-10-2023
Public Assessment Report Public Assessment Report Greek 07-03-2012
Patient Information leaflet Patient Information leaflet English 04-10-2023
Public Assessment Report Public Assessment Report English 07-03-2012
Patient Information leaflet Patient Information leaflet French 04-10-2023
Public Assessment Report Public Assessment Report French 07-03-2012
Patient Information leaflet Patient Information leaflet Italian 04-10-2023
Public Assessment Report Public Assessment Report Italian 07-03-2012
Patient Information leaflet Patient Information leaflet Latvian 04-10-2023
Public Assessment Report Public Assessment Report Latvian 07-03-2012
Patient Information leaflet Patient Information leaflet Lithuanian 04-10-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-10-2023
Public Assessment Report Public Assessment Report Lithuanian 07-03-2012
Patient Information leaflet Patient Information leaflet Hungarian 04-10-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 04-10-2023
Public Assessment Report Public Assessment Report Hungarian 07-03-2012
Patient Information leaflet Patient Information leaflet Maltese 04-10-2023
Public Assessment Report Public Assessment Report Maltese 07-03-2012
Patient Information leaflet Patient Information leaflet Dutch 04-10-2023
Public Assessment Report Public Assessment Report Dutch 07-03-2012
Patient Information leaflet Patient Information leaflet Polish 04-10-2023
Public Assessment Report Public Assessment Report Polish 07-03-2012
Patient Information leaflet Patient Information leaflet Portuguese 04-10-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 04-10-2023
Public Assessment Report Public Assessment Report Portuguese 07-03-2012
Patient Information leaflet Patient Information leaflet Romanian 04-10-2023
Public Assessment Report Public Assessment Report Romanian 07-03-2012
Patient Information leaflet Patient Information leaflet Slovak 04-10-2023
Public Assessment Report Public Assessment Report Slovak 07-03-2012
Patient Information leaflet Patient Information leaflet Finnish 04-10-2023
Public Assessment Report Public Assessment Report Finnish 07-03-2012
Patient Information leaflet Patient Information leaflet Swedish 04-10-2023
Public Assessment Report Public Assessment Report Swedish 07-03-2012
Patient Information leaflet Patient Information leaflet Norwegian 04-10-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 04-10-2023
Patient Information leaflet Patient Information leaflet Icelandic 04-10-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 04-10-2023
Patient Information leaflet Patient Information leaflet Croatian 04-10-2023

Search alerts related to this product

View documents history